Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 1.00 |
| ▸ | MMP9 | P14780 | 12/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 1.00 |
| ▸ | MMP13 | P45452 | 2/20 | 0.87 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.87 |
| ▸ | MMP1 | P03956 | 1/20 | 0.87 |
| ▸ | MMP3 | P08254 | 1/20 | 0.87 |
| ▸ | MMP7 | P09237 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 2/20 | 0.68 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
| ▸ | MMP14 | P50281 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545297 | 1.00 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL32691761 | 1.00 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4422501 | 0.93 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL14218256 | 0.93 | MMP2 (0.87) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL14533971 | 0.93 | MMP2 (0.87) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL14218257 | 0.93 | MMP2 (0.87) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4422490 | 0.93 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL697591 | 0.92 | MMP2 (0.85) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4188026 | 0.92 | MMP2 (0.85) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL697592 | 0.92 | MMP2 (0.85) | MMP2MMP9ADAMTS4MMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | claimed |
| US-20100092469-A1 | ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS | THE U.S. OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS | 2010-04-15 | — | — | US | claimed |
| EP-2114160-A1 | ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS | University of Maryland, Baltimore (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008098160-A1 | ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-08-14 | — | — | WO | claimed |
| US-12589090-B2 | Compounds and methods for the treatment of degenerative disorders | AQUILUS PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12121526-B2 | Targeting NCCA-ATP channel for organ protection following ischemic episode | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024028417-A1 | NEW COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF VITILIGO | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-02-08 | — | — | WO | disclosed |
| US-20210113589-A1 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-04-22 | — | — | US | disclosed |
| US-10898496-B2 | Targeting NCCa-ATP channel for organ protection following ischemic episode | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020154243-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20190117672-A1 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-04-25 | — | — | US | disclosed |
| US-20190111137-A1 | METHODS FOR ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-04-18 | — | — | US | disclosed |
| US-20040248813-A1 | Compounds and methods for the modulation of cd154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004105837-A2 | COMPOUNDS AND METHODS FOR IMPROVING PLATELET RECOVERY AND FUNCTION | CENTER FOR BLOOD RESEARCH, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040205837-A1 | Transgenic mouse over-expressing calreticulin (CRT) in vascular smooth muscle cells | MESAELI NASRIN | 2004-10-14 | — | — | US | disclosed |
| US-20040072750-A1 | Compounds and methods for the modulation of CD154 | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1399466-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040048803-A1 | Compounds and methods for the modulation of CD154 | PHILLIPS DAVID (US) | 2004-03-11 | — | — | US | disclosed |
| WO-2002089730-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | THE CENTER FOR BLOOD RESEARCH, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020165166-A1 | Compounds and methods for the modulation of CD154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589090-B2 | Compounds and methods for the treatment of degenerative disorders | CASP3, CASP10, CASP1 | MMP2 85/4885MMP9 244/4885ADAMTS4 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.